Director, Regulatory Affairs

Syndax Pharmaceuticals is looking for a Director, Regulatory Affairs

At Syndax, we are determined to realize a future in which people with cancer live longer and better than ever before. Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies.

The Role:

 The Director, Regulatory Affairs will be responsible for leading the development and implementation of a consolidated regulatory strategy (including regulatory operations) to secure and maintain market access for the assigned product through all development phases. The Director is also responsible for establishing and maintaining effective relationships with regulatory agencies, especially the FDA. This person will lead a team of regulatory professionals. and advise employees on regulatory requirements for all dosage forms and delivery systems and recommend appropriate actions.

Key Responsibilities:

• Develop and implement global regulatory strategy for assigned projects, along with Regional Regulatory Affairs representatives and Regulatory CMC.
• Represent Syndax and communicate on all regulatory issues involving the FDA and other regulatory health authorities for all products and businesses.
• Lead global and/or regional regulatory team on assigned projects.
• Provides Leadership to Regulatory department. Responsible for training, development of the current regulatory team, and selection and hiring of new team members.
• Develop and execute US regulatory strategy and contingencies for assigned projects.
• Serve as the primary interface for FDA on assigned projects.
• Responsible for the review and approval of Standard Operating Procedures (SOP) relating to preparation, submission and reporting information to regulatory authorities. Prepare, plan and implement new processes and policies to improve efficiency of the Company.
• Communicate project regulatory strategies and plans to management, cross functional teams and any partners/collaborators to establish alignment.
• Contribute to the development of competitive regulatory strategies that expedite development, maximize the probability of success, and mitigate risk.
• Lead the preparation of submissions, which may include INDs, Briefing Documents, Orphan Drug Applications, and Marketing Applications, etc. Work with functional groups to define contributions to submissions. Lead regulatory submission teams for assigned projects.
• Prepare company team for FDA and other health agency meetings, as required.
• Serve as the primary interface with Regulatory CROs for coordination and preparation of submissions.
• Maintain knowledge of global competitive landscape, regulatory environment, regulations and guidance.

Desired Experience/Education and Personal Attributes:

• Bachelor’s degree in scientific discipline; advanced scientific degree preferred.
• Regulatory Affairs Certification highly desirable.
• 10+ years pharmaceutical industry experience, including 7+ years in Regulatory Affairs leadership roles; Global experience desired.
• Experience in multiple phases of development in various therapeutic areas.
• Demonstrated experience in preparing FDA submissions.
• Knowledge of the drug development process and global submission process.
• Knowledge of global regulatory guidance as they relate to the overall global regulatory strategy.
• Inter-dependent partnering skills, team-oriented and ability to influence outcomes are necessary skills in the environment.
• Excellent organizational, communication and time management skills needed to manage multiple ongoing projects simultaneously.
• Must be able to innovate, analyze and solve problems with minimal supervision and attention to detail.

Location: Syndax has offices in Waltham, MA and New York City and has a dispersed workforce across the United States.

About Syndax:
Syndax Pharmaceuticals is a commercial stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib a highly selective menin inhibitor, and Niktimvo™ (axatilimab-csfr), a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment for both revumenib and Niktimvo. For more information, please visit www.syndax.com/ or follow the Company on X (formerly Twitter) and LinkedIn.

#LI-Remote